Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing

Two ROS1 tyrosine kinase inhibitors have been approved for ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) tumors. We performed a pan-tumor analysis of the incidence of ROS1 fusions to assess if more ROS1+patients who could benefit from ROS1 TKIs could be identified.